Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Key Highlights
- ➤34.4% of infants achieved vIGA-AD Success after four weeks of ZORYVE cream 0.05%
- ➤FDA review of infant indication has a February 23, 2027 PDUFA target action date
- ➤ZORYVE foam 0.3% cleared scalp psoriasis in 66.4% versus 27.8% with vehicle at Week 8
- ➤ZORYVE foam 0.3% cleared body psoriasis in 45.5% versus 20.1% with vehicle at Week 8
- ➤78.8% of adults and 77.6% of caregivers said corticosteroid treatment focused on flares, not long-term control
Expert Statements
Frank Watanabe, President and chief executive officer of Arcutis
“The data presented at these two meetings add to the growing body of evidence supporting ZORYVE across three chronic inflammatory skin conditions and a wide range of ages, including infants, the most vulnerable and underserved patient populations. The results include positive data for once-daily ZORYVE cream in infants ages 3 to 24 months with atopic dermatitis, and ZORYVE cream and foam in people with psoriasis, including genital involvement and the impact of disease on sexual function and personal relationships. We also shared new collaborative research on the pathophysiology of seborrheic dermatitis that further characterizes the cutaneous molecular signature of the disease.”
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis
“This growing body of research deepens our understanding of what long-term topical corticosteroid use means for people living with chronic inflammatory skin conditions. This includes findings from a real-world survey, presented at a medical congress for the first time, alongside a targeted review of the literature examining adverse events associated with topical corticosteroid use. Together, these data provide important context on treatment patterns, perceptions of disease control, and patient and caregiver concerns around long-term use, helping to inform continued discussions around responsible and appropriate topical corticosteroid use and steroid stewardship in the management of chronic inflammatory skin diseases.”
* Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited * New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's efficacy and symptom improvements across the body in individuals with psoriasis * Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis * Real-world research examines the role long-term topical corticosteroid use plays in the care of adults and children with chronic inflammatory skin conditions WESTLAKE VILLAGE, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced data presented across its ZORYVE(®) (roflumilast) portfolio as well as real-world research on the long-term use of topical corticosteroids at the 35(th) European Academy of Dermatology and Venereology (EADV) Congress, held Sept. 30-Oct. 3 in Vienna, Austria, and the Fall Clinical Dermatology Conference, held Oct. 8-11 in Las Vegas, Nevada.
Get started
Create a free account to read the full story.